WeLeader Biomedical Co

WeLeader Biomedical Co P/CF

The P/CF (Price-to-Cash-Flow Ratio) of WeLeader Biomedical Co (7713.TWO) as of Oct 20, 2026 is 10.31. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was 11.58 — a change of -11.02% (lower).

P/CF

10.31

YoY

-11.02%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of WeLeader Biomedical Co is 2025 10.31 . P/CF (Price-to-Cash-Flow Ratio) of WeLeader Biomedical Co was 2024 11.58 . It decreases by -11.02% lower compared to the previous year.

The WeLeader Biomedical Co P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2020
18.69 TWD
Jan 1, 2021
13.57 TWD
Jan 1, 2022
11.52 TWD
Jan 1, 2023
13.93 TWD
Jan 1, 2024
11.58 TWD
Jan 1, 2025
10.31 TWD
The WeLeader Biomedical Co P/CF history
YEARP/CFYoY
10.31-11.02%
11.58-16.82%
13.93+20.88%
11.52-15.07%
13.57-27.41%
18.69—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

WeLeader Biomedical Co Stock analysis

What does WeLeader Biomedical Co do? WeLeader Biomedical Co Ltd generates revenue through the agency and trading of in vitro diagnostic instruments and reagent-related products, primarily serving domestic markets. The company provides distribution, after-sales, and maintenance services for laboratory reagents, consumables, instruments, and equipment, alongside construction planning for medical testing laboratories. Additional services include equipment procurement, operational coaching, human resources training, and digital medical examination platforms. Domestic clients purchase these integrated solutions for healthcare facilities and laboratories. The firm's product portfolio focuses on medical testing-related services, including operational coaching and digital platform solutions, which are sold to healthcare institutions requiring comprehensive laboratory support. Distribution of in vitro diagnostic instruments and reagents forms a core revenue stream, supported by ancillary services like equipment procurement and site construction planning. These offerings target domestic healthcare providers seeking efficient laboratory management solutions. WeLeader Biomedical Co Ltd's business model combines product sales with service delivery, emphasizing domestic market penetration. The company's revenue is derived from both the sale of diagnostic instruments and reagents and the provision of specialized services such as operational coaching and digital platform access. Healthcare institutions and laboratories are the primary buyers of these integrated offerings, leveraging the company's expertise in laboratory construction and equipment maintenance. WeLeader Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about WeLeader Biomedical Co stock

P/CF (Price-to-Cash-Flow Ratio) of WeLeader Biomedical Co is 10.31 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of WeLeader Biomedical Co changed from 11.58 to 10.31, representing a -11.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) WeLeader Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s WeLeader Biomedical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — WeLeader Biomedical Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — WeLeader Biomedical Co